Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + etoposide + platinum
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Durvalumab + etoposide + platinum is a chemo-immunotherapy combination regimen being investigated for the treatment of limited-stage small-cell lung cancer (LS-SCLC). The regimen includes durvalumab (Imfinzi), a human monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and CD80, thereby restoring anti-tumor immune responses. This is combined with etoposide, a topoisomerase II inhibitor, and a platinum-based chemotherapy agent (either cisplatin or carboplatin) which causes DNA damage. In the CONCUR trial led by investigator Qian Chu, this combination is administered as induction therapy followed by concurrent chemoradiotherapy and durvalumab consolidation.
- Other names
- durvalumab + EPdurvalumab + etoposide + cisplatindurvalumab + etoposide + carboplatinCONCUR regimen
02
Targets
DNATOP2A (DNA topoisomerase II)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + etoposide + platinum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + etoposide + platinum.